[go: up one dir, main page]

MX2014002208A - Inhibidores de serina/treonina quinasa. - Google Patents

Inhibidores de serina/treonina quinasa.

Info

Publication number
MX2014002208A
MX2014002208A MX2014002208A MX2014002208A MX2014002208A MX 2014002208 A MX2014002208 A MX 2014002208A MX 2014002208 A MX2014002208 A MX 2014002208A MX 2014002208 A MX2014002208 A MX 2014002208A MX 2014002208 A MX2014002208 A MX 2014002208A
Authority
MX
Mexico
Prior art keywords
threonine
serine
pak1 inhibitors
pak1
inhibitors
Prior art date
Application number
MX2014002208A
Other languages
English (en)
Inventor
Wendy Lee
Ignacio Aliagas-Martin
James Crawford
Simon Mathieu
Joachim Rudolph
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014002208A publication Critical patent/MX2014002208A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos que tienen la fórmula I en donde A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb y n son como se define aquí, son inhibidores de PAK1. También se describen composiciones y métodos para tratar cáncer y desórdenes hiperproliferativos.(ver Fórmula).
MX2014002208A 2011-08-25 2012-08-24 Inhibidores de serina/treonina quinasa. MX2014002208A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161527453P 2011-08-25 2011-08-25
PCT/EP2012/066468 WO2013026914A1 (en) 2011-08-25 2012-08-24 Serine/threonine pak1 inhibitors

Publications (1)

Publication Number Publication Date
MX2014002208A true MX2014002208A (es) 2014-05-28

Family

ID=46799208

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002208A MX2014002208A (es) 2011-08-25 2012-08-24 Inhibidores de serina/treonina quinasa.

Country Status (11)

Country Link
US (1) US8637537B2 (es)
EP (1) EP2748159A1 (es)
JP (1) JP2014524456A (es)
KR (1) KR20140062079A (es)
CN (1) CN104024248A (es)
BR (1) BR112014003997A2 (es)
CA (1) CA2844729A1 (es)
HK (1) HK1197232A1 (es)
MX (1) MX2014002208A (es)
RU (1) RU2014109897A (es)
WO (1) WO2013026914A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110269856A (zh) 2010-03-30 2019-09-24 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
BR112014026952B1 (pt) * 2012-05-03 2022-03-15 Genentech, Inc Derivados de aminopirimidina pirazol e composição que os compreende
CN103724276A (zh) * 2013-12-13 2014-04-16 成都丽璟科技有限公司 一种由硝基苯胺制备苯并咪唑类化合物的新方法
WO2016025641A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and an egfr inhibitor and related methods
RU2017131562A (ru) * 2015-02-27 2019-03-27 Версеон Корпорейшн Замещенные пиразольные соединения как ингибиторы сериновых протеаз
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
US10851108B2 (en) 2016-04-20 2020-12-01 Bristol-Myers Squibb Company Substituted bicyclic heterocyclic compounds
US20200321533A1 (en) * 2016-05-24 2020-10-08 President And Fellows Of Harvard College Compounds for organic light emitting diode materials
WO2018108627A1 (de) 2016-12-12 2018-06-21 Bayer Cropscience Aktiengesellschaft Verwendung substituierter indolinylmethylsulfonamide oder deren salze zur steigerung der stresstoleranz in pflanzen
CA3056970A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
US20220274979A1 (en) 2018-04-18 2022-09-01 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
CN108689901B (zh) * 2018-05-05 2020-04-28 西北大学 一种氮杂环丙烯类化合物的合成方法
US20220363667A1 (en) 2018-07-17 2022-11-17 Nippon Chemiphar Co., Ltd. T-type calcium channel blocker
WO2020203609A1 (ja) 2019-03-29 2020-10-08 日本ケミファ株式会社 掻痒を治療するためのｔ型カルシウムチャネル阻害剤の使用
WO2020212484A1 (en) 2019-04-17 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
EP4073102A4 (en) 2019-12-12 2024-05-08 Ting Therapeutics LLC Compositions and methods for the prevention and treatment of hearing loss
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
CA3198468A1 (en) * 2020-10-30 2022-05-05 Daiichi Sankyo Company, Limited Production method for 3-methyl-4-haloindole derivatives
WO2023164612A1 (en) * 2022-02-25 2023-08-31 Nalo Therapeutics Modulators of myc family proto-oncogene protein
EP4628488A4 (en) * 2022-12-16 2026-01-21 Adlai Nortye Biopharma Co Ltd CYCLINE K DEGRADING AGENT AND ITS USE
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025078334A1 (en) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia
WO2025257786A1 (en) * 2024-06-13 2025-12-18 Iama Therapeutics S.R.L. Benzoimidazole derivatives as nkcc1 inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022607A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03005609A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
GB0128134D0 (en) 2001-11-23 2002-01-16 Syngenta Participations Ag A product for use in agriculture or horticulture
JP4741491B2 (ja) 2003-08-07 2011-08-03 ライジェル ファーマシューティカルズ， インコーポレイテッド 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
EP1763514A2 (en) 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
AU2005322855B2 (en) * 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
CN101208093A (zh) 2005-04-27 2008-06-25 阿斯利康(瑞典)有限公司 吡唑-嘧啶衍生物在治疗疼痛中的用途
AU2006248780B2 (en) * 2005-05-16 2010-06-03 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
EP1945631B8 (en) 2005-10-28 2013-01-02 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
CA2627808A1 (en) 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
ATE508126T1 (de) 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
AU2007269540B2 (en) 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
CA2685876A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
WO2008147626A2 (en) 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
EP2265270A1 (en) * 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
MX2012005332A (es) * 2009-11-13 2012-10-15 Oscotec Inc Inhibidores de cinasa.
JP2015504876A (ja) * 2011-12-22 2015-02-16 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト セリン／トレオニンキナーゼ阻害剤としての２，４−ジアミン−ピリミジン誘導体

Also Published As

Publication number Publication date
CN104024248A (zh) 2014-09-03
JP2014524456A (ja) 2014-09-22
US8637537B2 (en) 2014-01-28
US20130225620A1 (en) 2013-08-29
HK1197232A1 (en) 2015-01-09
KR20140062079A (ko) 2014-05-22
CA2844729A1 (en) 2013-02-28
RU2014109897A (ru) 2015-09-27
BR112014003997A2 (pt) 2017-03-21
EP2748159A1 (en) 2014-07-02
WO2013026914A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
MX2014002208A (es) Inhibidores de serina/treonina quinasa.
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX358376B (es) Nuevos derivados dihidroquinolina-2-ona.
MX340756B (es) Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
MX339873B (es) Inhibidores de serina/treonina cinasa.
PH12014500373A1 (en) Amino quinazolines as kinase inhibitors
PH12014501365A1 (en) Compounds
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
MX2015001720A (es) Hetero-azepinonas sustituidas.
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
MX2012008141A (es) Compuestos y metodos.
MY169267A (en) New aryl-quinoline derivatives
PH12015501038A1 (en) Inhibitors of iap
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
PH12015500345A1 (en) Amino-quinolines as kinase inhibitors
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
PH12016501071B1 (en) Serine/threonine kinase inhibitors
MX2014002832A (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
GEP201706687B (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
CR20140495A (es) 5-amino[1,4]thiazines como inhibidores de bace1
PH12015500399A1 (en) Azaindolines
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
IN2015DN02588A (es)